JP2009534408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009534408A5 JP2009534408A5 JP2009506751A JP2009506751A JP2009534408A5 JP 2009534408 A5 JP2009534408 A5 JP 2009534408A5 JP 2009506751 A JP2009506751 A JP 2009506751A JP 2009506751 A JP2009506751 A JP 2009506751A JP 2009534408 A5 JP2009534408 A5 JP 2009534408A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- compound
- alkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 34
- -1 cyano, cyanomethyl Chemical group 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 18
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 150000002367 halogens Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 10
- 150000002148 esters Chemical class 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 150000001412 amines Chemical class 0.000 claims 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 8
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 229910052740 iodine Inorganic materials 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical group [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 4
- 230000002062 proliferating effect Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical compound ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 claims 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 claims 1
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000004983 autoimmune atherosclerosis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001842 fibrogenetic effect Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 230000009036 growth inhibition Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000002147 killing effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 0 *c(cc1)cc(*)c1NC(C(N)=CN1*)=C(*)C1=O Chemical compound *c(cc1)cc(*)c1NC(C(N)=CN1*)=C(*)C1=O 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79312906P | 2006-04-18 | 2006-04-18 | |
| US60/793,129 | 2006-04-18 | ||
| PCT/US2007/066894 WO2007121481A2 (en) | 2006-04-18 | 2007-04-18 | Pyridone sulfonamides and pyridone sulfamides as mek inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009534408A JP2009534408A (ja) | 2009-09-24 |
| JP2009534408A5 true JP2009534408A5 (enExample) | 2010-06-03 |
| JP5269762B2 JP5269762B2 (ja) | 2013-08-21 |
Family
ID=38610466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506751A Expired - Fee Related JP5269762B2 (ja) | 2006-04-18 | 2007-04-18 | Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7897624B2 (enExample) |
| EP (1) | EP2012786B1 (enExample) |
| JP (1) | JP5269762B2 (enExample) |
| KR (1) | KR101391461B1 (enExample) |
| CN (1) | CN101454004B (enExample) |
| AT (1) | ATE483463T1 (enExample) |
| AU (1) | AU2007237901B2 (enExample) |
| BR (1) | BRPI0710817A2 (enExample) |
| CA (1) | CA2649122C (enExample) |
| DE (1) | DE602007009663D1 (enExample) |
| EA (1) | EA016674B1 (enExample) |
| ES (1) | ES2354182T3 (enExample) |
| IL (1) | IL194595A (enExample) |
| MX (1) | MX2008013097A (enExample) |
| WO (1) | WO2007121481A2 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2496565C (en) * | 2002-08-23 | 2013-04-02 | Ribapharm Inc. | Non-nucleoside reverse transcriptase inhibitors |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
| US7897624B2 (en) * | 2006-04-18 | 2011-03-01 | Ardea Biosciences | Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors |
| US7842836B2 (en) | 2006-04-11 | 2010-11-30 | Ardea Biosciences | N-aryl-N'alkyl sulfamides as MEK inhibitors |
| US8509487B2 (en) * | 2007-04-19 | 2013-08-13 | Avago Technologies General Ip (Singapore) Pte. Ltd. | System and method for optically measuring a parameter of an object |
| CA2924436A1 (en) * | 2007-07-30 | 2009-02-05 | Ardea Biosciences, Inc. | Pharmaceutical combinations of n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide as inhibitors of mek and methods of use |
| AR071587A1 (es) * | 2008-04-21 | 2010-06-30 | Novartis Ag | Compuestos heterociclicos como inhibidores de mek |
| UA107183C2 (uk) | 2008-08-04 | 2014-12-10 | Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань | |
| US9084781B2 (en) | 2008-12-10 | 2015-07-21 | Novartis Ag | MEK mutations conferring resistance to MEK inhibitors |
| UY32486A (es) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | Tratamiento del cáncer de páncreas |
| ES2543608T3 (es) * | 2009-03-27 | 2015-08-20 | Ardea Biosciences, Inc. | Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de MEK |
| CN102459188A (zh) * | 2009-06-15 | 2012-05-16 | 凯美隆(北京)药业技术有限公司 | 新型6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| TWI524890B (zh) | 2009-07-24 | 2016-03-11 | 亞德生化公司 | （ｒ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺及（ｓ）－ｎ－（３，４－二氟－２－（２－氟－４－碘苯胺基）－６－甲氧基苯基）－１－（２，３－二羥丙基）環丙烷－１－磺醯胺之製備 |
| US8349832B2 (en) * | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
| US8318737B2 (en) | 2009-09-02 | 2012-11-27 | Canthera Therapeutics Inc. | Compounds and compositions for treating cancer |
| US9034861B2 (en) | 2009-10-13 | 2015-05-19 | Allomek Therapeutics Llc | MEK inhibitors useful in the treatment of diseases |
| EA201200651A1 (ru) * | 2009-11-04 | 2012-12-28 | Новартис Аг | Гетероциклические сульфонамидные производные, применимые в качестве ингибиторов мек |
| MX340392B (es) | 2010-02-25 | 2016-07-06 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| CN102358730A (zh) * | 2011-08-24 | 2012-02-22 | 济南赛文医药技术有限公司 | 一种小分子mek蛋白激酶抑制剂 |
| CN103204827B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| EP2934572A4 (en) | 2012-12-20 | 2016-11-23 | Biomatrica Inc | FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS |
| EP3007556B1 (en) | 2013-06-13 | 2020-05-20 | Biomatrica, INC. | Cell stabilization |
| JP6661554B2 (ja) | 2014-06-10 | 2020-03-11 | バイオマトリカ，インク． | 周囲温度における血小板の安定化 |
| WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
| JP6827048B2 (ja) | 2015-12-08 | 2021-02-10 | バイオマトリカ，インク． | 赤血球沈降速度の低下 |
| US10366774B2 (en) | 2016-09-27 | 2019-07-30 | Spin Memory, Inc. | Device with dynamic redundancy registers |
| US10489245B2 (en) | 2017-10-24 | 2019-11-26 | Spin Memory, Inc. | Forcing stuck bits, waterfall bits, shunt bits and low TMR bits to short during testing and using on-the-fly bit failure detection and bit redundancy remapping techniques to correct them |
| US10411185B1 (en) | 2018-05-30 | 2019-09-10 | Spin Memory, Inc. | Process for creating a high density magnetic tunnel junction array test platform |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US12280055B2 (en) | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5596008A (en) * | 1995-02-10 | 1997-01-21 | G. D. Searle & Co. | 3,4-Diaryl substituted pyridines for the treatment of inflammation |
| US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DK0821671T3 (da) * | 1995-04-20 | 2001-04-23 | Pfizer | Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
| HUP9903014A3 (en) | 1996-07-18 | 2000-08-28 | Pfizer | Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same |
| US6153609A (en) | 1996-08-23 | 2000-11-28 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| AU5131998A (en) | 1997-01-06 | 1998-08-03 | Pfizer Inc. | Cyclic sulfone derivatives |
| ES2202796T3 (es) | 1997-02-03 | 2004-04-01 | Pfizer Products Inc. | Derivados de acidos arilsulfonilaminohidroxamicos. |
| JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
| BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| ID23668A (id) | 1997-08-08 | 2000-05-11 | Pfizer Prod Inc | Turunan asam ariloksiarilsulfonilamino hidroksamat |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| UA60365C2 (uk) * | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| ES2213985T3 (es) | 1998-11-05 | 2004-09-01 | Pfizer Products Inc. | Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico. |
| US6511993B1 (en) * | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
| GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
| AU2001290940A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
| WO2002044166A1 (en) * | 2000-11-02 | 2002-06-06 | Astrazeneca Ab | Substituted quinolines as antitumor agents |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| DE60330227D1 (de) * | 2002-03-13 | 2010-01-07 | Array Biopharma Inc | N3-alkylierte benzimidazol-derivate als mek-hemmer |
| US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
| WO2004011461A1 (en) * | 2002-07-25 | 2004-02-05 | Pfizer Products Inc. | Isothiazole derivatives useful as anticancer agents |
| JP2005162727A (ja) * | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| CN1905873A (zh) * | 2003-11-19 | 2007-01-31 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
| JP2006083137A (ja) * | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | 免疫抑制剤 |
| JP2006083133A (ja) * | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | スルファミド誘導体医薬組成物 |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US7897624B2 (en) | 2006-04-18 | 2011-03-01 | Ardea Biosciences | Pyridone sulfonamides and pyridone sulfamides as MEK inhibitors |
-
2007
- 2007-04-18 US US11/737,109 patent/US7897624B2/en not_active Expired - Fee Related
- 2007-04-18 ES ES07760859T patent/ES2354182T3/es active Active
- 2007-04-18 WO PCT/US2007/066894 patent/WO2007121481A2/en not_active Ceased
- 2007-04-18 AT AT07760859T patent/ATE483463T1/de not_active IP Right Cessation
- 2007-04-18 EA EA200870446A patent/EA016674B1/ru not_active IP Right Cessation
- 2007-04-18 BR BRPI0710817-6A patent/BRPI0710817A2/pt not_active IP Right Cessation
- 2007-04-18 CA CA2649122A patent/CA2649122C/en not_active Expired - Fee Related
- 2007-04-18 DE DE602007009663T patent/DE602007009663D1/de active Active
- 2007-04-18 MX MX2008013097A patent/MX2008013097A/es active IP Right Grant
- 2007-04-18 AU AU2007237901A patent/AU2007237901B2/en not_active Ceased
- 2007-04-18 JP JP2009506751A patent/JP5269762B2/ja not_active Expired - Fee Related
- 2007-04-18 EP EP07760859A patent/EP2012786B1/en active Active
- 2007-04-18 CN CN2007800193159A patent/CN101454004B/zh not_active Expired - Fee Related
-
2008
- 2008-10-07 IL IL194595A patent/IL194595A/en not_active IP Right Cessation
- 2008-11-18 KR KR1020087028158A patent/KR101391461B1/ko not_active Expired - Fee Related
-
2011
- 2011-01-19 US US13/009,052 patent/US8716318B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009534408A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| CN114430740A (zh) | Egfr抑制剂、组合物及其制备方法 | |
| JP2010539095A5 (enExample) | ||
| JP2011506402A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| EP3130585A2 (en) | Pyrrolo[3,2-d]pyrimidine-4-amine derivatives and related compounds for the treatment of cancer | |
| RU2006131591A (ru) | Способ получения 2-аминотиазол-5-ароматических карбоксамидов в качестве ингибиторов киназ | |
| JP2014520898A5 (enExample) | ||
| JP2016513137A5 (enExample) | ||
| JP2011509949A5 (enExample) | ||
| KR20180105700A (ko) | 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용 | |
| JP2008528467A5 (enExample) | ||
| JP2014513704A5 (enExample) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| JP2010523670A5 (enExample) | ||
| CA2545942A1 (en) | Aryl imidazoles and their use as anti-cancer agents | |
| JP2013502441A5 (enExample) | ||
| JP2020505356A5 (enExample) | ||
| JP2013199483A5 (enExample) | ||
| US20170015635A1 (en) | Disubstituted triazole analogs | |
| EA200800516A1 (ru) | Производные n-фенил-2-пиримидинамина и процесс их получения | |
| JP2015522551A5 (enExample) | ||
| IL197262A0 (en) | Anti cancer use of caffeic acid and its derivatives | |
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 |